Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Fezolinetant established the NK3 receptor antagonist class in vasomotor symptoms in 2023. Elinzanetant (combined NK1-NK3 receptor antagonist) carries approval with broader vasomotor and sleep-related symptom benefit data, and follow-on NK-pathway programs are in late-stage trials. The non-hormonal vasomotor therapy category has gone from one approved option to a competitive prescribing class in three years.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.